Transactions & Cases Detail
DiagnoCure announces closing of the PCA3 Asset Sale transaction and special distribution to its shareholders
February 26, 2016
Pharmaceutical / Bio Life Sciences
On February 17, 2016, DiagnoCure Inc. announced the closing of the previously announced sale of all assets related to DiagnoCure’s PCA3 prostate cancer biomarker to Hologic, Inc. via its wholly-owned subsidiary, Gen-Probe Incorporated (the “PCA3 Asset Sale”). In connection with the PCA3 Asset Sale, the Corporation has repurchased the 4,900,000 series A convertible preferred shares of DiagnoCure held by Gen-Probe Incorporated. DiagnoCure also announced today a return of capital distribution of C$0.1208 per share to its shareholders of record as at the close of business on February 26, 2016 in accordance with the policies of the Toronto Stock Exchange concerning the process and timeline.
McCarthy Tétrault LLP advised DiagnoCure with a team led by Philippe Leclerc.